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Abstract 
Background: Breast cancer is a major cause of death for women in Japan. The objectives of this study were to esti-
mate and project the economic burden associated with breast cancer in Japan and identify the key factors that drive 
the change of the economic burden of breast cancer.
Methods: We calculated the cost of illness (COI) every 3 years from 1996 to 2020 using governmental statistics. COI 
was calculated by summing the direct costs, morbidity costs, and mortality costs.
Results: From 1996 to 2011 COI was trending upward. COI in 2011 (697 billion yen) was 1.7-times greater than that 
in 1996 (407 billion yen). The mortality costs accounted for approximately 65–70 % of the total COI and were a major 
contributing factor to increase in COI. It was predicted that COI would continue to trend upwards until 2020 (699.4–
743.8 billion yen depending on the model), but the rate of increase would decline.
Conclusions: COI of breast cancer has been steadily increasing since 1996. While the rate of increase is expected to 
plateau, the average age at death from breast cancer is still less than that from other cancers, and the relative eco-
nomic burden of breast cancer will continue to increase in the foreseeable future.
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Background
Breast cancer (ICD 10 code: C50) is the most preva-
lent cancer among women and the fifth leading cause of 
death [1]. In the past, the prevalence and mortality rate of 
breast cancer has been lower in Japan than in the United 
States and Europe [2–4], but have been increasing rap-
idly [5–8]. The salient feature of breast cancer in Japanese 
women is that the peak incidence is in women in their 
late forties, whereas in the United States and Europe the 
peak incidence is in women over 60 years of age [9–11]. 
For this reason, breast cancer causes severe damage for 
Japanese women in the prime of their life, resulting in a 
high economic burden of treatment for breast cancer in 
Japan.
To date, only a few studies have attempted to estimate 
the economic burden of breast cancer in Japan [12, 13]. 
Moreover, most of them are limited to the estimation of 
direct medical expenses at a single time point. It is dif-
ficult to estimate the real social burden of a disease like 
breast cancer, where the incidence and mortality are 
high in younger women, using only the direct medical 
expenses.
In this study, we calculated direct costs as well as indi-
rect costs, which include the opportunity cost because of 
disease and death. The goal was to adequately capture the 
social burden of breast cancer by estimating past trends 
and projecting future trends in the costs of breast can-
cer. We already tried to calculate COI of several cancers 
in the past [14]. But this study performed more detailed 
analysis of breast cancer and tried to project COI in the 
near future.
A previous study calculated the cost of illness (COI) of 
stomach cancer in Japan [15]. The COI calculations pub-
lished for 1996, 2002, 2008, 2014, and 2020 concluded 
that COI decreased continuously until 2008. This is likely 
because of the devaluation of human capital with aging, 
particularly approaching the average age of death. The 
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study further concluded that COI would continue to 
decrease in the near future.
Comparing with stomach cancer, the social burden of 
breast cancer is expected to increase. We compare our 
COI estimates for breast cancer with those for stomach 




The COI method is well described for measuring the 
social burden of disease [16–22]. In this study, COI was 
calculated from 1996 to 2011 and, based on these data, 
future projections were made for 2014–2020 to evaluate 
trends over time.
The COI calculation is dependent on three variables: 
direct costs, morbidity costs, and mortality costs. The 
direct costs are defined as medical expenses (treatment 
costs, hospital charges, laboratory costs, drug costs, etc.). 
In this study, we used reimbursement data from the “Sur-
vey of National Medical Care Insurance Services” to cal-
culate annual medical expenses.
The morbidity costs are associated with inpatient care 
and outpatient care. The morbidity costs of inpatients 
were calculated by multiplying total person-days of hos-
pitalization by the 1-day labor-value per person. The 
morbidity costs of outpatients were calculated by mul-
tiplying total person-days of outpatient visits by half the 
1-day labor-value per person. Total person-days of out-
patient visits and hospitalization according to sex and 
5 years age-groups were calculated based on the “Patient 
Survey”. The labor-value was calculated according to sex 
and 5 years age-groups using the “Basic Survey on Wage 
Structure”, “Labor Force Survey”, and “Estimates of mon-
etary valuation of unpaid work”.
The mortality costs are measured as the loss of human 
capital (human capital method), which was calculated by 
multiplying the number of deaths by the lifetime labor-
value per person. The number of deaths caused by breast 
cancer according to sex and 5  years age-groups was 
obtained from “Vital Statistics”. The lifetime labor-value 
was calculated by summing the income, which the person 
could have earned in the future if they had not died, from 
the year of death to life expectancy. The future labor-
value was adjusted to a present value using a 3 % discount 
rate.
Future projection of COI
Predictions of future COI from 2014 to 2020 were based 
on the “Population Projection for Japan: 2011–2060 (Jan-
uary 2012)” by the National Institute of Population and 
Social Security Research. The year 2011 was selected 
as the benchmark for the 1-day labor-value by sex and 
5  years age-groups. Two methods were utilized for the 
future projection of COI. The first is the “fixed” method, 
which fixes health-related indicators (the mortality rate, 
number of times of outpatient visit per population, num-
ber of times of hospitalization per population, and aver-
age length of stay) of each age-group at the 2011 level and 
changes future population and age structure. The other 
is the “variable” method, which estimates health-related 
indicators in addition to population and age structure. 
Future health-related indicators are estimated using lin-
ear regression (linear model), logarithmic regression 
(logarithmic model), or a combination of regressions of 
higher coefficient of determination (mixed model). The 
details of the methodology are outlined in the COI study 
of stomach cancer [15]. The present study found that the 
mixed model was the most valid.
This study used only aggregated data, and did not use 
human or animals. In Japan, for this kind of study no 
institutional review is requested [23].
Results
COI from 1996 to 2011
Table 1 shows the trend of COI and health-related indica-
tors from 1996 to 2011. COI was calculated to be 697 bil-
lion yen (≒6.97 billion dollar) in 2011. The contribution 
of the direct costs, morbidity costs, and mortality costs 
were 116.3 billion yen, 46.8 billion yen, and 484.0 billion 
yen, respectively. The mortality costs were the greatest 
contributors and accounted for 69.4 % of the total COI. 
COI increased continuously from 1996 to 2011 by 3.6 % 
annually for a total increase of 1.7-times. The direct costs 
increased until 2005 and decreased gradually after. The 
morbidity costs were almost constant, but the mortality 
costs, which accounted for approximately 70  % of COI, 
increased consistently. The contribution ratio of the mor-
tality cost to total increase was 62.8 %.
Increased mortality costs were the primary factor con-
tributing to increased COI. Because the mortality cost 
per person (mortality cost/the number of deaths) was 
stable (36.9–41.2 million yen), it is likely that the increase 
in the number of deaths directly led to increases in the 
mortality costs. According to the National Cancer Center 
of Japan, the number of deaths increased 61.2  % from 
1996 to 2011 [1]. The increase was continuous with an 
annual percent change (APC) of 3.2  %. The crude mor-
tality rate showed a 58.3  % increase from 12.4 (per 100 
thousand persons) in 1996 to 19.7 (per 100 thousand per-
sons) in 2011. The crude incidence rate increased 2-times 
from 47.9 (per 100 thousand persons) in 1996 to 99.5 (per 
100 thousand persons) in 2008, while the fatality rate 
decreased.
Table  2 shows the comparison of the mortality rate, 
number of deaths, and incidence rate according to sex and 
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5 years age-groups between 1996 and 2011. The mortality 
rate showed almost no increase in persons younger than 
55 years, but there was a large increase (>30 % increase) 
in persons aged 55 years and older. Moreover, aging of the 
population accelerated the increase in the mortality rate 
in older persons. As a result, the number of deaths, aver-
age age at death, and associated mortality costs increased 
for persons aged 65  years or older (Table  1). Finally, the 
rate of increase exceeded 100 % in the 75–79 age-group.
Future projection of COI from 2014 to 2020 (fixed model)
Table  3 shows the future projection of COI based on a 
fixed model. COI was estimated to be 704.7 billion yen 
in 2014, 705.9 billion yen in 2017, and 703.4 billion yen 
in 2020; thereby increasing until 2017 and then decreas-
ing in 2020. The rate of change from 2011 to 2020 was 
0.9  %. The direct costs increased until 2020, whereas 
the morbidity costs decreased in 2017 and the mortality 
costs decreased from 2014. The rate of change for each 
component was stable during these 10 years at less than 
5  %. Nonetheless, the mortality costs per person were 
projected to decrease continuously.
The fixed model assumes that health-related indicators 
were fixed at 2011 levels and only demographic changes 
had any impact on COI. According to the National Insti-
tute of Population and Social Security Research, the 
Table 1 Trend of the cost of illness (COI) of breast cancer
Source of population: Ministry of Internal Affairs and Communications “Population Estimates”. Source of the number of breast cancer deaths: “Vital Statistics”. Average 
age of death: calculated according to the number of deaths, sex and age (5 years old age grade), cause of death in “Vital Statistics”. Source of crude morbidity rate and 
crude mortality rate: Center for Cancer Control and Information Services, National Cancer Center, Japan. Fatality rate: we calculated by dividing the crude mortality 
rate by crude morbidity rate
NA not available
1996 1999 2002 2005 2008 2011
Population (thousand person) 125,864 126,686 127,435 127,768 127,692 127,799
[% of 65 years or older] 15.1 % 16.7 % 18.5 % 20.2 % 22.1 % 23.1 %
Number of breast cancer deaths (person) 7,900 8,882 9,604 10,721 11,797 12,731
[% of 65 years or older] 36.3 % 37.7 % 40.5 % 43.7 % 48.6 % 52.0 %
Average age of death (years) 60.1 61.0 62.1 63.3 64.8 66.1
Crude incidence rate (per 100 thousand, female) 47.9 54.4 64.4 77.5 99.5 NA
Crude mortality rate (per 100 thousand, female) 12.4 13.9 14.9 16.6 18.3 19.7
Fatality rate (female) 0.26 0.25 0.23 0.21 0.18 NA
Direct cost (billion yen) 72.2 124.9 146.8 185.4 168.6 166.3
Morbidity cost (billion yen) 33.3 40.1 49.0 43.7 47.2 46.8
Mortality cost (billion yen) 302.8 328.4 395.9 415.7 435.6 484.0
[% of 65 years or older] 11.2 % 11.5 % 14.8 % 16.2 % 19.3 % 23.1 %
Mortality cost per person (million yen) 38.3 37.0 41.2 38.8 36.9 38.0
COI (billion yen) 408.4 493.3 591.6 644.8 651.3 697.0
Table 2 Mortality rate and the number of deaths due to breast cancer (1996 and 2011)
Source of the number of breast cancer deaths: “Vital Statistics”. Source of crude morbidity rate and mortality rate: Center for Cancer Control and Information
25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85
Crude mortality rate (per 100 thousand, female)
 1996 0.6 2.2 7.0 11.7 18.8 26.3 25.2 24.6 25.2 24.2 24.2 25.2 34.3
 2011 0.5 1.9 4.9 10.2 18.9 27.7 37.2 37.1 37.0 32.4 33.2 41.0 53.7
 Changing rate −22.4 % −11.9 % −30.5 % −12.6 % 0.6 % 5.1 % 47.5 % 51.1 % 46.5 % 34.1 % 37.2 % 62.6 % 56.8 %
Number of breast cancer deaths (person)
 1996 27 85 265 494 1042 1120 1036 963 873 692 507 385 408
 2011 16 75 228 461 735 1043 1545 2000 1509 1241 1146 1117 1567
 Changing rate −40.7 % −11.8 % −14.0 % −6.7 % −29.5 % −6.9 % 49.1 % 107.7 % 72.9 % 79.3 % 126.0 % 190.1 % 284.1 %
Crude incidence rate (per 100 thousand, female)
 1996 4.3 12.8 38.2 71.5 115.4 89.5 83.1 80.4 81.9 85.1 73.9 66.6 59.8
 2008 8.1 28.1 57.5 130.9 195.7 179.6 177.4 183.9 176.2 155.3 134.7 127.3 108.2
 Changing rate 87.5 % 119.4 % 50.6 % 82.9 % 69.5 % 100.6 % 113.5 % 128.7 % 115.1 % 82.4 % 82.2 % 91.2 % 80.9 %
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Japanese population began to decrease in 2008 and it 
was estimated to continue to decrease until 2020, while 
the rate of aging was estimated to rise [24]. Under these 
conditions, the number of deaths from breast cancer was 
estimated to increase by 8.7 % (APC of 0.9 %) from 2011 
to 2020. The number of deaths in persons aged 65 years 
or older was predicted to increase by 7.4 % and the aver-
age age at death was also predicted to rise by 1.8 years. 
In the fixed model, the mortality rate of 2014, 2017 and 
2020 was fixed at 2011 level, and it was considered that 
increase of aged population had impact on such aging of 
persons who died by breast cancer.
Future projection of COI from 2014 to 2020 (variable 
model)
Using a linear model, COI in 2014, 2017, and 2020 was 
estimated to be 714.1 billion yen, 731.1 billion yen, and 
743.6 billion yen, respectively. Using a logarithmic model 
Table 3 Mortality rate and the number of deaths due to breast cancer (1996 and 2011)
Source of estimated population: 2008; Ministry of Internal Affairs and Communications “Population Estimates” 2014 2020; National Institute of Population and Social 
Security Research “Population Statistics of Japan”
Model Item 2011 2014 2017 2020
Estimated population (thousand person) 127,799 126,949 125,739 124,223
[% of 65 years or older] 23.1 % 26.1 % 28.0 % 29.1 %
Fixed model Number of breast cancer deaths (person) 12,791 13,308 13,641 13,901
[% of 65 years or older] 52.1 % 56.2 % 58.7 % 59.4 %
Average age of death (years) 66.1 66.8 67.4 67.9
Direct cost (billion yen) 166.3 168.3 170.0 170.1
Morbidity cost (billion yen) 46.8 48.6 48.7 48.4
Mortality cost (billion yen) 484.0 487.8 487.2 484.8
[% of 65 years or older] 23.1 % 25.6 % 27.0 % 26.7 %
Mortality cost per person (million yen) 38.0 36.7 35.7 34.9
COI (billion yen) 697.0 704.7 705.9 703.4
Linear model Number of breast cancer deaths (person) 12,791 13,968 15,015 16,039
[% of 65 years or older] 52.1 % 56.0 % 59.4 % 60.8 %
Average age of death (years) 66.1 66.9 67.9 68.7
Direct cost (billion yen) 166.3 157.4 158.3 160.6
Morbidity cost (billion yen) 46.8 47.3 49.3 46.5
Mortality cost (billion yen) 484.0 509.5 523.5 536.4
[% of 65 years or older] 23.1 % 25.5 % 27.7 % 28.2 %
Mortality cost per person (million yen) 38.0 36.5 34.9 33.4
COI (billion yen) 697.0 714.1 731.1 743.6
Logarithm model Number of breast cancer deaths (person) 12,791 13,153 13,720 14,222
[% of 65 years or older] 52.1 % 54.6 % 57.4 % 58.5 %
Average age of death (years) 66.1 66.4 67.1 67.8
Direct cost (billion yen) 166.3 158.8 154.7 153.0
Morbidity cost (billion yen) 46.8 45.8 44.3 44.0
Mortality cost (billion yen) 484.0 494.6 499.5 502.4
[% of 65 years or older] 23.1 % 24.2 % 25.7 % 25.7 %
Mortality cost per person (million yen) 38.0 37.6 36.4 35.3
COI (billion yen) 697.0 699.2 698.5 699.4
Mixed model Number of breast cancer deaths (person) 12,791 13,555 14,323 14,986
[% of 65 years or older] 52.1 % 54.2 % 56.8 % 57.4 %
Average age of death (years) 66.1 66.3 67.0 67.5
Direct cost (billion yen) 166.3 157.1 159.6 162.2
Morbidity cost (billion yen) 46.8 45.5 46.5 47.3
Mortality cost (billion yen) 484.0 510.9 524.0 534.3
[% of 65 years or older] 23.1 % 24.4 % 26.1 % 25.9 %
Mortality cost per person (million yen) 38.0 37.7 36.6 35.7
COI (billion yen) 697.0 713.5 730.0 743.8
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the predictions were valued at 699.2 billion yen, 698.5 
billion yen, and 699.4 billion yen, respectively, and lastly, 
using a mixed model, COI in 2014, 2017, and 2020 was 
estimated to be 713.5 billion yen, 730.0 billion yen, and 
743.8 billion yen, respectively. Figure 1 shows the trends 
of COI based on the fixed model as well as the 3 variable 
models.
Since the trend of each health related indicator was 
different, the monotype estimation (logarithmic model 
or linear model) might not predict future COI precisely. 
The mixed model was a combination of models of higher 
coefficient of determination and, therefore, considered 
the most valid model in this study. According to this 
mixed model, COI showed a 6.7 % (APC: 0.7 %) increase 
from 2011 to 2020. The direct and morbidity costs were 
stable, but the mortality costs increased 10.4  % (APC: 
1.1  %). As the number of deaths increased by 17.2  % 
(APC: 1.8  %), the mortality costs per person decreased 
continuously. Figure  2 shows the trends of each COI 
component in each model.
Comparison with COI of stomach cancer
Our previous study of COI of stomach cancer estimated 
COI in 1996, 2002, 2008, 2014, and 2020 using the year 
2008 as the benchmark. In that study, COI was estimated 
to be 1114.2 billion yen (direct costs: 253.7 billion yen, 
morbidity costs: 54.0 billion yen, and mortality costs: 806.4 
billion yen) in 2008 and was predicted to decrease to 484.5 
billion yen in 2020 using a mixed model (direct costs: 100.4 
billion yen, morbidity costs: 26.4 billion yen, and mortality 
costs: 357.7 billion yen). The decrease in COI from 2008 to 
2020 was 56.5 % (APC: 8.8 %), and the mortality cost was 
also predicted to decrease by 55.6 % (APC: 8.6). However, 
there was a large variation in COI estimation (70.1 % varia-
tion to COI in 2008) by each method [12].
Compared with COI of stomach cancer, COI of breast 
cancer was smaller in the benchmark year but was pre-
dicted to increase continuously to be 1.5-times that of 
stomach cancer by 2020. The mortality costs of breast 
cancer were estimated to be smaller, but were predicted 
to be 1.5-times those of stomach cancer. Moreover, there 
was less variation in the estimation of COI of breast can-
cer, which was only 6.4 % of the benchmark year’s COI. 
Each estimation method showed that COI of breast can-
cer was stable or increased modestly.
Discussion
The results of this study demonstrated that COI of breast 
cancer increased significantly from 1996 to 2011. The 
increase in the mortality costs contributed significantly. 
Furthermore, it was predicted that COI would continue 
to trend upwards until 2020, but the rate of increase 
would decline. The annual average rate of increase was 
3.8  % from 1996 to 2011 but was predicted to be only 
0.7 % from 2011 to 2020 in the mixed model. Because the 
variation in the model was small, we can conclude that 
future COI will be stable or increase only slightly.
COI and the mortality costs of breast cancer are pre-
dicted to exceed those of stomach cancer in the near 
future. Changes in the number of deaths and the aver-
age age at death were the main causes of the increase 
in the mortality costs. Because the mortality costs were 
calculated as the number of deaths multiplied by the 
mortality costs per person (lifetime labor-value per per-
son) according to sex and 5 age-groups, the increase 
in the number of deaths had a direct influence on the 
increase in the mortality costs. Additionally, the lifetime 
labor-value per person (or human capital value) dif-
fers according to the average age at death. Because the 
human capital value of the 25 to 29-age-group was the 
highest, an increase in the average age at death resulted 
in decreased mortality costs. Regarding the number of 
deaths from benchmark year to 2020, for stomach can-
cer, there was a 25.1 % decrease (APC: −2.4 %), and con-
versely, for breast cancer, there was a 17.2  % increase 
(APC: 1.8). Nonetheless, the number of deaths from 
stomach cancer was predicted to be 37,581, whereas 
that from breast cancer was predicted to be only 14,986. 





































































Fig. 2 The cost of illness (COI) projections with cost elements
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to be 9.5 million yen for stomach cancer and 35.7 mil-
lion yen for breast cancer. This difference is most likely 
because of the difference in the average age at death, 
which was predicted to be 79.1  years for stomach can-
cer and 67.5 years (11.6 years younger) for breast cancer 
in 2020. Moreover, while the annual rate of increase in 
the average age at death from stomach cancer was stable 
before and after the benchmark year (0.5 %), the annual 
rate of increase in the average age at death from breast 
cancer declined after the benchmark year (from 0.6 to 
0.2 %).
There are two types of cancers: one affects an “older 
group” (74.8 years old for stomach cancer, 74.6 years 
old for lung cancer, 75.6  years old for colon cancer, 
and so on in 2011) and the other affects a “younger 
group” (66.1  years old for breast cancer, 67.6  years 
old for cervical cancer, and so on in 2011) [14]. The 
trends of the mortality rates by age suggest that 
the rate of increase of the average age at death will 
probably rise for the older group and decline for the 
younger group. Accordingly, the mortality costs per 
person and COI will probably decrease for the older 
group and increase for the younger group. These 
results may be very useful for prioritizing policies for 
cancer control.
The effectiveness of mammography for the detection 
of breast cancer has already been proven by several stud-
ies [25, 26]. While the assessment of technology is out-
side the scope of this study, our results demonstrate the 
importance of allocating subsidies to such countermeas-
ures preferentially to implement efficient policy.
There are some limitations to this study that compli-
cate the interpretation of the data used for approxima-
tions. Firstly, the study period was relatively short and 
there were dramatic changes within the healthcare sys-
tem during this time. However, the variation among the 
different methods for determining projections was small 
and, therefore, the projections are likely to be accurate 
for the near future. Additionally, we could not predict 
future increases in the labor-value per person, particu-
larly with regard to the employment and compensation 
rates for women, which are likely to rise. When these 
are taken into account, COI of breast cancer is likely to 
increase even more, which would only further strengthen 
our conclusions.
Conclusions
The findings of the present study suggest that COI of 
breast cancer has continuously increased up to the pre-
sent and that trend is likely to continue, although the 
pace may be expected to decline. The average age at 
death from breast cancer was less than that from other 
cancers and the pace of aging was slow. These factors 
contribute to increasing the social burden of breast can-
cer, making it clear that policies to mitigate these effects 
are critical.
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